At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02509 QYUNS-B
Trading 08-12 14:52:52
17.720
-0.040
-0.23%
High18.000Low17.540Vol33.00K
Open17.570D1 Closing17.760Amplitude2.59%
Mkt Cap3.95BTradable Cap3.95BTotal Shares223.00M
T/O584.44KT/O Rate0.01%Tradable Shares223.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Qyuns Therapeutics to Review 1H26 Interim Results at 19 August Board Meeting
Bulletin Express  ·  08-07
Qyuns Therapeutics to Review 1H26 Interim Results at 19 August Board Meeting
Qyuns Therapeutics Says China Clears Qx027n Trials for COPD
Reuters  ·  07-31
Qyuns Therapeutics Says China Clears Qx027n Trials for COPD
Qyuns Therapeutics Co - QX027n Obtains Two Clinical Trial Approvals for Copd and Chronic Rhinosinusitis
THOMSON REUTERS  ·  07-31
Qyuns Therapeutics Co - QX027n Obtains Two Clinical Trial Approvals for Copd and Chronic Rhinosinusitis
Qyuns Therapeutics Partner Caldera to Merge with Synlogic
MT Newswires Live  ·  07-30
Qyuns Therapeutics Partner Caldera to Merge with Synlogic
QYUNS-B (02509) Partner Caldera Therapeutics Plans Nasdaq Listing via Synlogic Merger with $278 Million Concurrent Fundraising Round
Stock News  ·  07-29
QYUNS-B (02509) Partner Caldera Therapeutics Plans Nasdaq Listing via Synlogic Merger with $278 Million Concurrent Fundraising Round
QYUNS-B Updates on Partner Caldera: USD278.00 Million Private Placement Secured Ahead of Planned Nasdaq Listing via Merger with Synlogic
Bulletin Express  ·  07-29
QYUNS-B Updates on Partner Caldera: USD278.00 Million Private Placement Secured Ahead of Planned Nasdaq Listing via Merger with Synlogic
QYUNS-B Executes HK$15.99 On-Market Buyback; Issued Float Dips to 223.37 Million Shares
Bulletin Express  ·  07-17
QYUNS-B Executes HK$15.99 On-Market Buyback; Issued Float Dips to 223.37 Million Shares
QYUNS-B (02509) Spends Approximately HK$16,000 on Share Buyback on July 17
Stock News  ·  07-17
QYUNS-B (02509) Spends Approximately HK$16,000 on Share Buyback on July 17
Qyuns Therapeutics Files HKEX Next-day Disclosure Reporting Share Buyback
Reuters  ·  07-17
Qyuns Therapeutics Files HKEX Next-day Disclosure Reporting Share Buyback
QYUNS-B (02509) Repurchases 3,000 Shares for Approximately HK$45,200 on July 9
Stock News  ·  07-09
QYUNS-B (02509) Repurchases 3,000 Shares for Approximately HK$45,200 on July 9
Qyuns Therapeutics Files HKEX Next-day Disclosure Return on Share Repurchase for Treasury Shares at HKD 15.08
Reuters  ·  07-09
Qyuns Therapeutics Files HKEX Next-day Disclosure Return on Share Repurchase for Treasury Shares at HKD 15.08
Qyuns Therapeutics Executes Minor Share Buyback; Adds 600 H-Shares to Treasury at HKD 15.70 Each
Bulletin Express  ·  07-08
Qyuns Therapeutics Executes Minor Share Buyback; Adds 600 H-Shares to Treasury at HKD 15.70 Each
QYUNS-B Buys Back 8,000 H Shares, Boosts Treasury Stock to 3.70 Million
Bulletin Express  ·  07-07
QYUNS-B Buys Back 8,000 H Shares, Boosts Treasury Stock to 3.70 Million
Qyuns Therapeutics Files HKEX Next-day Disclosure Return After Share Repurchase for Cancellation
Reuters  ·  07-07
Qyuns Therapeutics Files HKEX Next-day Disclosure Return After Share Repurchase for Cancellation
QYuns-B Shares Surge Over 8% Following CLD-423 Injection Clinical Trial Approval and Progress in Overseas Licensing
Stock News  ·  07-06
QYuns-B Shares Surge Over 8% Following CLD-423 Injection Clinical Trial Approval and Progress in Overseas Licensing
Qyuns Therapeutics Executes HKD 45,812 Share Buyback, Lifts Treasury Stock to 3.69 Million Shares
Bulletin Express  ·  06-30
Qyuns Therapeutics Executes HKD 45,812 Share Buyback, Lifts Treasury Stock to 3.69 Million Shares
QYUNS-B Repurchases Shares for Approximately HK$45,800
Stock News  ·  06-30
QYUNS-B Repurchases Shares for Approximately HK$45,800
Qyuns Therapeutics Files HKEX Next-day Disclosure Reporting Share Repurchase for Treasury Shares
Reuters  ·  06-30
Qyuns Therapeutics Files HKEX Next-day Disclosure Reporting Share Repurchase for Treasury Shares
QYUNS-B Shares Surge Over 8% on Plan to Acquire Remaining Stake in CMC Subsidiary to Advance Core Drug Filings
Stock News  ·  06-29
QYUNS-B Shares Surge Over 8% on Plan to Acquire Remaining Stake in CMC Subsidiary to Advance Core Drug Filings
Qyuns Therapeutics to Acquire Remaining 34.00% Stake in Cellularforce for RMB 86.02 Million, Moving to Full Ownership
Bulletin Express  ·  06-26
Qyuns Therapeutics to Acquire Remaining 34.00% Stake in Cellularforce for RMB 86.02 Million, Moving to Full Ownership
No data available

Introduction

Company Name.
QYUNS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Qyuns Therapeutics Co Ltd is a China-based company principally engaged in the research and development, manufacturing and commercialisation of biologic therapies for autoimmune and allergic diseases. The Company focuses on dermatology, respiratory, gastroenterology and rheumatology diseases. The Company's products include SAILEXIN, Oturkibart, and Crusekitug. The Company conducts its businesses in domestic and overseas markets.
Issue price:
--